Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
China channel feed
Qiming, Hillhouse bet on Jacobio's nascent pipeline of first-in-class drug hopefuls in $55M round
7 years ago
Financing
As the maiden biotech IPO on the HKEX fizzles, some investment experts see an upside in tempering the hype
7 years ago
Financing
Pharma
Harbour BioMed follows cancer drug deals with a hefty $85M Series B backed by Singapore's GIC
7 years ago
Financing
Newborn biobetter, biosimilar maker Mabpharm pitches the latest biotech IPO in Hong Kong
7 years ago
Financing
Bristol-Myers will sell Opdivo in China at half of US cost, setting precedent for checkpoint wave — report
7 years ago
Pharma
Right on the heels of $150M raise, Ascentage files the latest in a rush of HKEX biotech IPOs — but is the market too jittery?
7 years ago
Financing
Harbour BioMed jumps into the crowded PD-1/L1 race, looking to take a Chinese asset global as checkpoint pipeline bulges
7 years ago
R&D
Pharma
Roche picks up a speedy nod in China as regulators follow through on plans for a fast 48 new drug OKs
7 years ago
Pharma
Former head of China's FDA booted in wake of searing vaccine scandal as leaders impose 'severe punishment'
7 years ago
R&D
Let's go to China: Join Endpoints in Shanghai for the first US-China Biopharma Innovation & Investment Summit — October 22-23 #BIIS18
7 years ago
Publisher's note
Eyes on China stocks: Loncar loads new ETF with his picks for most promising biotechs on HKEX and Nasdaq
7 years ago
Pharma
Gilead loses key patent claims for Sovaldi in China, opening door to earlier generic entry
7 years ago
China regulators offer VIP treatment for 48 overseas drugs they're ready to hustle up with accelerated reviews
7 years ago
Pharma
Touting its manufacturing strengths, Tot Biopharm raises $102M mega-round to ramp up cancer R&D
7 years ago
Financing
BeiGene takes a hit after historic $903M Hong Kong IPO with negative biotech sentiment
7 years ago
Financing
Lilly Asian Ventures backs Impact's PARP research again, chipping in for $30M Series C led by Decheng Capital
7 years ago
Financing
BeiGene bags a staggering $903M IPO on the HKEX — and still manages to spark some nervous fretting
7 years ago
Financing
Ascletis breaks into HKEX, briefly rising on hotly anticipated public debut of first biotech
7 years ago
Financing
Fresh out of 6 Dimensions' incubator, Curon launches with $150M and backing from Boyu, Temasek
7 years ago
Financing
In for the China biotech gold rush, BeiGene eyes monster $800M-plus Hong Kong IPO
7 years ago
Financing
Ascletis reaps record $400M from Hong Kong investors in the exchange's first-ever pre-revenue biotech listing
7 years ago
Financing
Pre-revenue vaccine developer CanSino lines up at a buzzing HKEX
7 years ago
Financing
On its way to making Hong Kong history, Ascletis eyes $457M haul in GIC-backed IPO
7 years ago
Financing
Fast-growing Ascentage has big plans for its latest $150M raise -- but what about the IPO?
7 years ago
Financing
First page
Previous page
23
24
25
26
27
28
29
Next page
Last page